Dr. Josh Rosenblat, chief medical and science officer of Toronto-based Braxia Scientific, has been awarded funding by the Canadian Institute of Health Research (CIHR) to support a first-of-its-kind ketamine clinical trial for bipolar depression, the company has announced.
The fully funded study, which the company claims is the largest registered trial of its kind in the world, will investigate the use, safety and efficacy of repeated doses of intravenous ketamine in patients with bipolar depression.
Just under three per cent of Canadians have a profile consistent with bipolar disorder, according to Statistics Canada. It is a leading cause of treatment-resistant depression and suicidality.
Story continues below
This advertisement has not loaded yet, but your article continues below.
The trial will
Read full article on The Growth Op